MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4
TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months
NEW YORK, NY, USA I April 28, 2017 I TG Therapeutics, Inc. (NASDAQ:TGTX) today announced preliminary results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS). The data is being presented today at the 69th American Academy of Neurology (AAN) annual meeting, taking place in Boston, MA. The poster is available for viewing during poster session 6, from 8:30 AM – 5:30 PM ET.
The poster, entitled “Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion“ (Abstract Number: 3113; Poster number 6.348), includes data from 24 patients with RMS treated with TG-1101. Three dosing cohorts of up to 8 patients each were evaluated to assess the safety and tolerability of TG-1101 at accelerated infusion times.
Highlights from the poster include:
- TG-1101 was well tolerated with no Grade 3/4 adverse events observed and the most commonly report AE being infusion related reactions, with median time on study of 5 months
- All scheduled doses were fully delivered to all subjects to date
- The independent DSMB reviewed safety data for each cohort periodically and approved continuation of the study at each review based on acceptable safety measures
- All patients met the primary end-point of >95% B-cell depletion by 4 weeks
- The median B-cell depletion at week 4 was 99% after two infusions (Day 1 and 15) with a cumulative dose of 600mg, which compares favorably with other anti-CD20 monoclonal antibodies
“We are highly encouraged by the data presented today demonstrating that TG-1101 is a potent and effective B-cell depleting agent. With the recent approval of ocrelizumab, B-cell depletion therapy is now recognized as a highly efficacious treatment option for patients with MS. We look forward to following these patients and reporting on established MS efficacy endpoints later this year, which require longer-term follow-up,” stated Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer. Mr. Weiss continued, “We believe TG-1101 represents an exciting option in the treatment of MS and believe this Phase 2 trial sets the stage for our Phase 3 program that we expect to commence in the coming months.”
“Information gained from this Phase 2 ublituximab trial has helped guide the development of the Phase 3 program, and will further the process of gaining a new innovative treatment option for patients with MS. The investigators in the clinical trial are pleased with the results thus far, and look forward to the full data set in the future,” stated Edward Fox, MD, PhD, Director of the Multiple Sclerosis Clinic of Central Texas and Clinical Assistant Professor at the University of Texas Medical Branch in Round Rock, TX, and the Principal Investigator for this Phase 2 study.
“The preliminary analysis of the immune profiles demonstrate efficient B-cell depletion occurs with ublituximab therapy. We are excited by the potential of ublituximab to provide patients with another treatment option and look forward to further exploring the immune profiling data to perhaps shed light on how B-cell depletion ameliorates MS progression. Understanding how B-cell depletion alters the immune response may also help us understand mechanisms that underlie the pathology of MS, also an area that is not fully understood,” stated Amy Lovett-Racke, PhD, Professor of the Department of Microbial Infection and Immunity at the Ohio State University Medical Center in Columbus, OH.
POSTER PRESENTATION DETAILS
A copy of the poster presentation is available on the Company’s website at www.tgtherapeutics.com, located on the Publications Page, within the Pipeline section.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
SOURCE: TG Therapeutics
Post Views: 162
MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4
TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months
NEW YORK, NY, USA I April 28, 2017 I TG Therapeutics, Inc. (NASDAQ:TGTX) today announced preliminary results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS). The data is being presented today at the 69th American Academy of Neurology (AAN) annual meeting, taking place in Boston, MA. The poster is available for viewing during poster session 6, from 8:30 AM – 5:30 PM ET.
The poster, entitled “Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion“ (Abstract Number: 3113; Poster number 6.348), includes data from 24 patients with RMS treated with TG-1101. Three dosing cohorts of up to 8 patients each were evaluated to assess the safety and tolerability of TG-1101 at accelerated infusion times.
Highlights from the poster include:
- TG-1101 was well tolerated with no Grade 3/4 adverse events observed and the most commonly report AE being infusion related reactions, with median time on study of 5 months
- All scheduled doses were fully delivered to all subjects to date
- The independent DSMB reviewed safety data for each cohort periodically and approved continuation of the study at each review based on acceptable safety measures
- All patients met the primary end-point of >95% B-cell depletion by 4 weeks
- The median B-cell depletion at week 4 was 99% after two infusions (Day 1 and 15) with a cumulative dose of 600mg, which compares favorably with other anti-CD20 monoclonal antibodies
“We are highly encouraged by the data presented today demonstrating that TG-1101 is a potent and effective B-cell depleting agent. With the recent approval of ocrelizumab, B-cell depletion therapy is now recognized as a highly efficacious treatment option for patients with MS. We look forward to following these patients and reporting on established MS efficacy endpoints later this year, which require longer-term follow-up,” stated Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer. Mr. Weiss continued, “We believe TG-1101 represents an exciting option in the treatment of MS and believe this Phase 2 trial sets the stage for our Phase 3 program that we expect to commence in the coming months.”
“Information gained from this Phase 2 ublituximab trial has helped guide the development of the Phase 3 program, and will further the process of gaining a new innovative treatment option for patients with MS. The investigators in the clinical trial are pleased with the results thus far, and look forward to the full data set in the future,” stated Edward Fox, MD, PhD, Director of the Multiple Sclerosis Clinic of Central Texas and Clinical Assistant Professor at the University of Texas Medical Branch in Round Rock, TX, and the Principal Investigator for this Phase 2 study.
“The preliminary analysis of the immune profiles demonstrate efficient B-cell depletion occurs with ublituximab therapy. We are excited by the potential of ublituximab to provide patients with another treatment option and look forward to further exploring the immune profiling data to perhaps shed light on how B-cell depletion ameliorates MS progression. Understanding how B-cell depletion alters the immune response may also help us understand mechanisms that underlie the pathology of MS, also an area that is not fully understood,” stated Amy Lovett-Racke, PhD, Professor of the Department of Microbial Infection and Immunity at the Ohio State University Medical Center in Columbus, OH.
POSTER PRESENTATION DETAILS
A copy of the poster presentation is available on the Company’s website at www.tgtherapeutics.com, located on the Publications Page, within the Pipeline section.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
SOURCE: TG Therapeutics
Post Views: 162
